Distinct Mechanisms for Inhibition of SARS-CoV-2 Main Protease: Dimerization Promoted by Peptidomimetic Inhibitors and Disrupted by Ebselen
This study reveals that peptidomimetic inhibitors promote SARS-CoV-2 main protease dimerization by rigidifying the interface, whereas ebselen disrupts dimerization via an allosteric covalent modification at C300, highlighting distinct inhibitory mechanisms for future drug design.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Viruses are masters of disguise and efficiency, but they rely on a few critical tools to survive and multiply. One of the most important tools for the virus that causes COVID-19 is an enzyme called the main protease. Think of this enzyme as a molecular pair of scissors. When the virus enters a human cell, it releases a long, useless chain of proteins. The main protease's job is to cut this chain into smaller, functional pieces that the virus needs to build new copies of itself. Without these cuts, the virus cannot reproduce. Because this enzyme is so essential and looks very similar across many different types of coronaviruses, scientists have spent years trying to find drugs that can jam its blades. Most of the successful drugs found so far work by fitting directly into the enzyme's cutting site, blocking it like a stone in a gear. However, this enzyme has a unique quirk: it only works when two copies of itself are locked together in a pair, known as a dimer. If the two halves fall apart, the enzyme stops working. This raises a fascinating question for drug designers: could we stop the virus not just by blocking the scissors, but by preventing the two halves from holding hands in the first place?
A team of researchers at The Hong Kong Polytechnic University set out to explore this question by watching how different drugs interact with the SARS-CoV-2 main protease. They wanted to see if the drugs they tested did more than just block the active cutting site. Using a sophisticated technique that allows them to weigh protein molecules while they are still in their natural, working state, the scientists observed how the enzyme behaved when mixed with various inhibitors. They found that the drugs fell into two very different camps. The first group, which includes well-known antiviral compounds like nirmatrelvir, acted in a way that reinforced the enzyme's structure. When these drugs bound to the enzyme, they didn't just stop the cutting; they actually made the two halves of the enzyme stick together more tightly. The researchers saw that the enzyme became more rigid and stable, effectively locking the pair in place. This suggests that these drugs work by stabilizing the enzyme's shape, making it impossible for the two halves to separate, which paradoxically keeps the enzyme in a state where it cannot function because it is locked in a complex with the drug.
In a striking contrast, the researchers discovered that a different drug, called ebselen, worked by doing the exact opposite. Instead of helping the two halves of the enzyme hold on, ebselen pushed them apart. When the scientists added ebselen to the mix, the enzyme's two halves began to fall apart, shifting the balance toward a single, inactive unit. To understand how this happened, the team looked closely at the enzyme's structure and found that ebselen attaches itself to a specific spot on the enzyme that is far away from the cutting site. This spot is located on the very edge where the two halves usually connect. By attaching to this distant location, ebselen acts like a wedge, forcing the two halves apart and making the connection between them unstable. The researchers confirmed this by creating a version of the enzyme where this specific attachment point was removed; without this point, ebselen lost much of its ability to break the enzyme apart. This discovery reveals a new way to fight the virus: instead of trying to jam the scissors, you can pull the handles apart so they can never work together again.
The study also provided a detailed look at how these drugs change the flexibility of the enzyme. Using a method that tracks how water molecules move across the protein's surface, the team saw that the drugs that stabilized the enzyme made it stiff and rigid, while ebselen made the enzyme floppy and loose. This difference in flexibility explains why the drugs have such different effects. The rigid drugs lock the enzyme in a compact, inactive shape, while the loose drug allows the enzyme to fall apart. The researchers also used computer simulations to model how ebselen attaches to the enzyme and confirmed that this attachment disrupts the delicate network of bonds that hold the two halves together. While ebselen is already known to have anti-inflammatory properties and has been tested in humans for other conditions, this study highlights a specific, previously unknown way it can disable the coronavirus. By identifying this new mechanism, the researchers have opened a door for designing future drugs that target the weak points where the enzyme halves connect, offering a potential strategy to outsmart viruses that might develop resistance to drugs that only block the cutting site.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.